Corporate Overview - Aldeyra Therapeutics focuses on developing innovative therapies for immune-mediated diseases by modulating protein systems rather than directly inhibiting single protein targets[7,8] - As of September 30, 2025, Aldeyra had $753 million in cash, cash equivalents, and marketable securities, expected to fund the company into the second half of 2027[10] RASP Modulation Platform - Aldeyra's approach involves modulating Reactive Aldehyde Species (RASP), which are formed by oxidation and bind to proteins, leading to pro-inflammatory signaling cascades[14] - RASP modulation allows for control of protein systems without completely turning single proteins on or off, potentially leading to broader activity with less toxicity[20,22] - ADX-629, an orally administered RASP modulator, has shown statistically significant changes in lipid profiles in multiple clinical trials, including a Phase 1 trial (P=0.005 for HDL), a Phase 2 psoriasis trial (P=0.036 for LDL/HDL ratio and P=0.0004 for FFA)[33] - ADX-248 binds to pro-inflammatory RASP HNE, leading to cytokine reduction in LPS-challenged mice and improved epidermal erosion scores in an oxazolone mouse model of atopic dermatitis (P=0.0093)[38] - ADX-248 increased brain dopamine and improved motor function in a preclinical Parkinson's disease model, with significant P values at different doses (P=0.05, P=0.001, P=0.004)[42] - ADX-246 binds to RASP retinaldehyde, reducing the toxic retinaldehyde metabolite A2E (P=0.04) in an Abcr knockout mouse model of dry AMD[44] Reproxalap - Reproxalap, a RASP modulator for dry eye disease, showed rapid activity in clinical trials and achieved the primary endpoint of ocular discomfort in a Phase 3 dry eye chamber trial (P=0.002)[48,53] - Aldeyra has an exclusive option agreement with AbbVie Inc for reproxalap, including a potential $100 million upfront payment, a $100 million milestone payment upon FDA approval in dry eye disease, and $200 million in additional regulatory and commercial milestones[61] - Phase 3 INVIGORATE allergen chamber trials for allergic conjunctivitis showed that reproxalap achieved the primary endpoint of patient-reported ocular itching with all P values < 0.0001[63] ADX-2191 - ADX-2191 has the potential to be the first approved drug for primary vitreoretinal lymphoma (PVRL), with approximately 200-600 new cases diagnosed in the United States per year[71]

RT DogeDesigner (@cb_doge)A paralyzed man was able to use his mind to control a robotic arm and feed himself.Thanks to Neuralink. ❤️https://t.co/A4PW0zM2OH ...

千亿产业有机联动，从实验室到生产线、从竞赛场到大市场，创新之火在这里燎原。12月16日，以"全球创新 浙里赋能"为主题的首届全球技术创新大赛颁 奖仪式在杭州举行。大赛聚焦人形机器人、生物制造、AI+眼健康、航空航天四大前沿领域，自今年7月启动以来，共吸引全球640余个创新项目报名参赛。 经多轮评审与路演比拼，29个项目分获一、二、三等奖。 本届大赛由浙江大学、西湖大学、浙江省经济和信息化厅共同主办，面向全球高校、科研机构及初创企业，鼓励具有产业化前景的原创技术在浙转化落地， 服务"全球创新、浙江转化"目标，推动培育新质生产力、加快构建现代化产业体系。 图为浙江省经济和信息化厅副厅长黄旭荣为颁奖仪式致辞 浙江省经济和信息化厅副厅长黄旭荣在致辞中表示，举办大赛旨在破解高端技术供给不足、转化链条不畅等问题，获奖项目体现出鲜明的原创性与产业化潜 力，不少团队携国际经验选择浙江作为创业首站。"我们一定会竭尽全力，秉持'有求必应、无事不扰'的理念，你负责扎根梦想，我负责阳光雨露。"黄旭荣 说，浙江将持续优化创新生态，畅通成果转化渠道，助力更多创新成果实现产业化。 转自：新华财经 图为项目合作签约环节 大会同步推进项目签约 ...

The after-hours market delivered a mixed but generally positive tone on Tuesday evening, with several small- and mid-cap names posting modest gains. One biotech, however, stole the spotlight with a dramatic surge following major clinical news.DBV Technologies S.A. (DBVT) dominated the after-hours session, soaring 61.29% to $29.00, up $11.02, after announcing a pivotal clinical milestone. The company reported that VITESSE, its Phase 3 study evaluating the VIASKIN Peanut patch in peanut-allergic children age ...

Core Points - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors of uniQure N.V. [1] - On November 3, 2025, uniQure announced that the FDA indicated insufficient evidence from its AMT-130 gene therapy studies to support a Biologics License Application (BLA) [2] - Following this announcement, uniQure's stock price dropped over 50%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3] Company Summary - uniQure N.V. is focused on developing gene therapies, specifically for conditions like Huntington's disease [2] - The company is currently facing challenges regarding the regulatory approval process for its investigational therapy AMT-130 [2] Legal and Regulatory Context - The investigation by Kessler Topaz Meltzer & Check, LLP highlights potential legal implications for uniQure related to securities laws [1] - The FDA's feedback on the adequacy of clinical trial data for AMT-130 raises concerns about the company's future regulatory submissions [2]

Core Viewpoint - Immunome, Inc. has announced a public offering of 18,625,000 shares of its common stock priced at $21.50 per share, with all shares being sold by the company [1] Company Summary - The public offering aims to raise gross proceeds for Immunome, which will be used for its targeted cancer therapies development [1] - The offering is underwritten, indicating that a financial institution is involved in the sale of the shares [1]

Core Points - Neurocrine Biosciences held its 2025 R&D Day, emphasizing the importance of the event for stakeholders [1] - The event featured key executives including the CEO, Chief Medical Officer, and Chief Scientific Officer, highlighting the leadership team's experience [2][3] - Dr. John Krystal, a prominent figure in neurology and psychiatry, participated in the event, indicating the company's commitment to collaboration with leading experts [3]

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on December 15, 2025, the Compensation Committee of Sutro’s Board of Directors granted stock options to purchase 24,500 shares of Sutro common stock and 2,000 restricted stock units (RSUs) to new non-executive employees. The grants were made as an inducement ...

 Kelowna, British Columbia – December 16, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 2,661,600 shares of its common stock, par value $0.001 per share, at a purchase price of $1.315 per share. In addition, in a concurrent private placement, the Company issued unregiste ...

Aurinia Pharmaceuticals Inc. ( AUPH ) has had an exciting few months, with an earnings update showing continued Lupkynis growth, a competitor's drug being approved for lupus nephritis, and a request for information from the FDA. I rated AUPH aScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclo ...